FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893602866> ?p ?o ?g. }

• W2893602866 endingPage "1479" @default.
• W2893602866 startingPage "1468" @default.
• W2893602866 abstract "Antibodies targeting the immune checkpoint molecules PD-1 or PD-L1 have demonstrated clinical efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). In this trial we investigated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with NSCLC who had already received platinum-based therapy.JAVELIN Lung 200 was a multicentre, open-label, randomised, phase 3 trial at 173 hospitals and cancer treatment centres in 31 countries. Eligible patients were aged 18 years or older and had stage IIIB or IV or recurrent NSCLC and disease progression after treatment with a platinum-containing doublet, an Eastern Cooperative Oncology Group performance status score of 0 or 1, an estimated life expectancy of more than 12 weeks, and adequate haematological, renal, and hepatic function. Participants were randomly assigned (1:1), via an interactive voice-response system with a stratified permuted block method with variable block length, to receive either avelumab 10 mg/kg every 2 weeks or docetaxel 75 mg/m2 every 3 weeks. Randomisation was stratified by PD-L1 expression (≥1% vs <1% of tumour cells), which was measured with the 73-10 assay, and histology (squamous vs non-squamous). The primary endpoint was overall survival, analysed when roughly 337 events (deaths) had occurred in the PD-L1-positive population. Efficacy was analysed in all PD-L1-positive patients (ie, PD-L1 expression in ≥1% of tumour cells) randomly assigned to study treatment (the primary analysis population) and then in all randomly assigned patients through a hierarchical testing procedure. Safety was analysed in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT02395172. Enrolment is complete, but the trial is ongoing.Between March 24, 2015, and Jan 23, 2017, 792 patients were enrolled and randomly assigned to receive avelumab (n=396) or docetaxel (n=396). 264 participants in the avelumab group and 265 in the docetaxel group had PD-L1-positive tumours. In patients with PD-L1-positive tumours, median overall survival did not differ significantly between the avelumab and docetaxel groups (11·4 months [95% CI 9·4-13·9] vs 10·3 months [8·5-13·0]; hazard ratio 0·90 [96% CI 0·72-1·12]; one-sided p=0·16). Treatment-related adverse events occurred in 251 (64%) of 393 avelumab-treated patients and 313 (86%) of 365 docetaxel-treated patients, including grade 3-5 events in 39 (10%) and 180 (49%) patients, respectively. The most common grade 3-5 treatment-related adverse events were infusion-related reaction (six patients [2%]) and increased lipase (four [1%]) in the avelumab group and neutropenia (51 [14%]), febrile neutropenia (37 [10%]), and decreased neutrophil counts (36 [10%]) in the docetaxel group. Serious treatment-related adverse events occurred in 34 (9%) patients in the avelumab group and 75 (21%) in the docetaxel group. Treatment-related deaths occurred in four (1%) participants in the avelumab group, two due to interstitial lung disease, one due to acute kidney injury, and one due to a combination of autoimmune myocarditis, acute cardiac failure, and respiratory failure. Treatment-related deaths occurred in 14 (4%) patients in the docetaxel group, three due to pneumonia, and one each due to febrile neutropenia, septic shock, febrile neutropenia with septic shock, acute respiratory failure, cardiovascular insufficiency, renal impairment, leucopenia with mucosal inflammation and pyrexia, infection, neutropenic infection, dehydration, and unknown causes.Compared with docetaxel, avelumab did not improve overall survival in patients with platinum-treated PD-L1-positive NSCLC, but had a favourable safety profile.Merck and Pfizer." @default.
• W2893602866 created "2018-10-05" @default.
• W2893602866 creator A5000105178 @default.
• W2893602866 creator A5001231739 @default.
• W2893602866 creator A5003664573 @default.
• W2893602866 creator A5008516429 @default.
• W2893602866 creator A5018054038 @default.
• W2893602866 creator A5021704329 @default.
• W2893602866 creator A5023874099 @default.
• W2893602866 creator A5030107272 @default.
• W2893602866 creator A5055100979 @default.
• W2893602866 creator A5071853292 @default.
• W2893602866 creator A5073572288 @default.
• W2893602866 creator A5081023613 @default.
• W2893602866 creator A5083662358 @default.
• W2893602866 creator A5086784581 @default.
• W2893602866 creator A5087492988 @default.
• W2893602866 creator A5087836238 @default.
• W2893602866 creator A5091509029 @default.
• W2893602866 creator A5091542924 @default.
• W2893602866 date "2018-11-01" @default.
• W2893602866 modified "2023-10-18" @default.
• W2893602866 title "Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study" @default.
• W2893602866 cites W2019607817 @default.
• W2893602866 cites W2023758807 @default.
• W2893602866 cites W2039485722 @default.
• W2893602866 cites W2071066672 @default.
• W2893602866 cites W2104347254 @default.
• W2893602866 cites W2156353875 @default.
• W2893602866 cites W2198093519 @default.
• W2893602866 cites W2293531514 @default.
• W2893602866 cites W2301488980 @default.
• W2893602866 cites W2368001341 @default.
• W2893602866 cites W2410864298 @default.
• W2893602866 cites W2474562936 @default.
• W2893602866 cites W2567564314 @default.
• W2893602866 cites W2599354912 @default.
• W2893602866 cites W2604441970 @default.
• W2893602866 cites W2625395613 @default.
• W2893602866 cites W2745683917 @default.
• W2893602866 cites W2753065806 @default.
• W2893602866 cites W2762777471 @default.
• W2893602866 cites W2766425839 @default.
• W2893602866 cites W2789502254 @default.
• W2893602866 cites W2803847828 @default.
• W2893602866 cites W2804957255 @default.
• W2893602866 doi "https://doi.org/10.1016/s1470-2045(18)30673-9" @default.
• W2893602866 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30262187" @default.
• W2893602866 hasPublicationYear "2018" @default.
• W2893602866 type Work @default.
• W2893602866 sameAs 2893602866 @default.
• W2893602866 citedByCount "317" @default.
• W2893602866 countsByYear W28936028662018 @default.
• W2893602866 countsByYear W28936028662019 @default.
• W2893602866 countsByYear W28936028662020 @default.
• W2893602866 countsByYear W28936028662021 @default.
• W2893602866 countsByYear W28936028662022 @default.
• W2893602866 countsByYear W28936028662023 @default.
• W2893602866 crossrefType "journal-article" @default.
• W2893602866 hasAuthorship W2893602866A5000105178 @default.
• W2893602866 hasAuthorship W2893602866A5001231739 @default.
• W2893602866 hasAuthorship W2893602866A5003664573 @default.
• W2893602866 hasAuthorship W2893602866A5008516429 @default.
• W2893602866 hasAuthorship W2893602866A5018054038 @default.
• W2893602866 hasAuthorship W2893602866A5021704329 @default.
• W2893602866 hasAuthorship W2893602866A5023874099 @default.
• W2893602866 hasAuthorship W2893602866A5030107272 @default.
• W2893602866 hasAuthorship W2893602866A5055100979 @default.
• W2893602866 hasAuthorship W2893602866A5071853292 @default.
• W2893602866 hasAuthorship W2893602866A5073572288 @default.
• W2893602866 hasAuthorship W2893602866A5081023613 @default.
• W2893602866 hasAuthorship W2893602866A5083662358 @default.
• W2893602866 hasAuthorship W2893602866A5086784581 @default.
• W2893602866 hasAuthorship W2893602866A5087492988 @default.
• W2893602866 hasAuthorship W2893602866A5087836238 @default.
• W2893602866 hasAuthorship W2893602866A5091509029 @default.
• W2893602866 hasAuthorship W2893602866A5091542924 @default.
• W2893602866 hasConcept C121608353 @default.
• W2893602866 hasConcept C126322002 @default.
• W2893602866 hasConcept C143998085 @default.
• W2893602866 hasConcept C203092338 @default.
• W2893602866 hasConcept C2776256026 @default.
• W2893602866 hasConcept C2776694085 @default.
• W2893602866 hasConcept C2776907518 @default.
• W2893602866 hasConcept C2777063308 @default.
• W2893602866 hasConcept C2777381376 @default.
• W2893602866 hasConcept C2777701055 @default.
• W2893602866 hasConcept C2780057760 @default.
• W2893602866 hasConcept C2781190966 @default.
• W2893602866 hasConcept C2908647359 @default.
• W2893602866 hasConcept C535046627 @default.
• W2893602866 hasConcept C71924100 @default.
• W2893602866 hasConcept C99454951 @default.
• W2893602866 hasConceptScore W2893602866C121608353 @default.
• W2893602866 hasConceptScore W2893602866C126322002 @default.
• W2893602866 hasConceptScore W2893602866C143998085 @default.
• W2893602866 hasConceptScore W2893602866C203092338 @default.
• W2893602866 hasConceptScore W2893602866C2776256026 @default.

• next